Arrowhead Pharmaceuticals


Arrowhead Pharmaceuticals is a publicly traded biopharmaceutical company based in Pasadena, California. Arrowhead’s products in development act through RNA interference mechanisms of action. The company focuses on treatments for Hepatitis B, the liver disease associated with alpha 1-antitrypsin deficiency and cardiovascular disease. The company has eight products in its pipeline, in various stages of development.
ProductIndicationDevelopment phaseNotes
ARO-HBVHepatitis BIn Clinic Phase 1/2Partnered with Janssen
ARO-AATAlpha-1 Antirypsin DeficiencyIn Clinic Phase 1/2Orphan Drug Designation
ARO-APOC3HypertriglyceridemiaPre-ClinicalOrphan Drug Designation
ARO-HIF2Renal Cell CarcinomaPre-Clinical-
ARO-ENaCCystic FibrosisPre-Clinical-
ARO-ANG3DyslipidemiaPre-ClinicalOrphan Drug Designation
AMG 890Cardiovascular DiseaseIn Clinic Phase 1/2Partnered with Amgen
ARO-AMG1Undisclosed CardiovascularPre-ClinicalPartnered with Amgen

In 2015, the company substantially expanded its intellectual property holdings through complete acquisition of the full RNAi research and development portfolio, and assets from Novartis.
In April 2016, it was announced that the former company name, Arrowhead Research Corporation, will be changed to Arrowhead Pharmaceuticals, Inc.
In September 2016, Arrowhead entered into two collaboration and licensing agreements with Amgen. Under the deals, Amgen received a worldwide exclusive license to Arrowhead’s ARO-LPA RNAi program and an option to a worldwide exclusive license for ARO-AMG1, both for cardiovascular disease.
On Oct. 31, 2018, Arrowhead Pharmaceuticals Inc. closed on a $3.7 Billion License and Collaboration Agreements with Janssen to develop and commercialize ARO-HBV. As part of the overall deal, Arrowhead entered into a research collaboration and option agreement with Janssen to potentially collaborate for up to three additional RNA interference therapeutics against new targets to be selected by Janssen.